Ulf Göran Richenberg

Esselte AB manufactures office solutions. It sells office products and graphics products. The company was founded on April 18, 1913 and is headquartered in Solna, Sweden.

Vattenfall AB engages in the generation, distribution, and sale of heat and electricity. It operates through the following segments: Heat, Customers and Solutions, Wind, Power Generation, and Distribution. The company was founded in 1909 and is headquartered in Solna, Sweden.

Part of Karolinska Institutet Holding AB, Nätverk Karolinska Institutet Science Park AB (KISP) facilitates interaction between academia and industry on Campus Solna. The company is based in Solna, Sweden. KISP collaborates closely with Karolinska Institutet, Akademiska Hus, and AWL to organize seminars, workshops, and networking events that help researchers, startups, and established companies connect and gain new insights. The CEO of the Swedish company is Karl Johan Ingvar Weigelt.

Scribona AB manufactures and distributes computers, operating systems, servers, and network products. The company's principal activities are the retail and distribution of computer products and high-tech office equipment such as PCs, handheld devices, printers, software and accessories.The company produces office products, office electronics information services in the Nordic countries. The company has five subsidiaries in Sweden, Luxemburg, UK, Finland and Norway. The company was founded in 1992 and is headquartered in Stockholm, Sweden

Avaris was founded in 2001 by research teams at the Karolinska Institute and Karolinska Innovations AB. The company is based on four proprietary technology platforms within cell and gene therapy. Avaris drives the research development and commercialization of new therapies in close collaboration with the founders, research teams, and strategic partners. The company is well positioned in cell and gene therapy field for chronic infections, cancer and inherited diseases. Avaris vision is to become the number one supplier of individualized cell and gene therapy treatments in northern Europe. In order to reach this goal it is exploring possibilities to acquire, or in license cell therapy technologies that complement the in house growth. Avaris is also open to partnering possibilities.